Please login to the form below

Not currently logged in
Email:
Password:

RNA

This page shows the latest RNA news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly to acquire Protomer Technologies in a deal worth over $1bn

Eli Lilly to acquire Protomer Technologies in a deal worth over $1bn

In May, Lilly agreed another $1bn-plus deal with MiNA Therapeutics, to develop therapies using its small activating RNA (saRNA) technology platform.

Latest news

More from news
Approximately 5 fully matching, plus 150 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

  • New hires at Abbott, Kite and Arrakis Therapeutics New hires at Abbott, Kite and Arrakis Therapeutics

    Arrakis Therapeutics . Arrakis Therapeutics, a biopharmaceutical company focused on the discovery of new-class small molecules medicines targeting RNA, has appointed Katrine Bosley (pictured below, right) as. ... Katrine’s experience building dynamic,

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    Professor Cech’s career has seen him spend decades researching into RNA biology and he became the scientific founder of Ribozyme Pharmaceuticals. ... As a leader in the field of RNA biology, Tom’s in-depth knowledge, insight and experience will be

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    standing experience in drug discovery and development at big pharma will help Storm maximise the potential of our pipeline and harness the power of RNA epigenetics as a new area of

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.

  • Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair Silence Therapeutics appoints Dr Annalisa Jenkins as non-executive chair

    RNA-focused group Silence Therapeutics has appointed Dimension Therapeutics chief executive officer Dr Annalisa Jenkins as the non-executive chair of its board of directors.

More from appointments
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...